Bachrodt Amy has reported the acquisition of stock options worth 399,746 shares in Lycia Therapeutics, Inc. This significant transaction, filed on October 26, 2026, is crucial as it aligns executive compensation with the company's long-term performance.
Lycia Therapeutics, Inc., identified under the Central Index Key 0001806540, operates within the biological products industry. The company is headquartered in South San Francisco, California, and focuses on innovative therapies in the life sciences sector. The recent filing indicates that Amy Bachrodt serves as the Chief Financial Officer and is recognized as a ten-percent owner of the company.
The filing details that the stock options were granted at an exercise price of $3.70 per share, with the transaction date recorded as August 11, 2026. Following the transaction, Bachrodt now owns a total of 399,746 shares. The options are set to vest over time, with a quarter of the total award vesting on June 2, 2027, and the remainder vesting monthly thereafter, contingent upon continued service to the company.
This acquisition may impact various stakeholders, including investors and employees, as it reflects the company's strategy to incentivize its executives. The biological products industry, which includes other companies focused on innovative therapies, may also feel the ripple effects of this executive move, prompting similar actions among peers.
The filing does not say what happens next regarding further transactions or company announcements.